Figure 1.

Study design. ^aPatients received ixekizumab 160 mg (given as two 80 mg subcutaneous injections) at Week 0 and then ixekizumab 80 mg Q2W until Week 12. Note: patients with erythrodermic psoriasis or generalized pustular psoriasis received the same treatment regimen throughout the Maintenance Dosing and Retreatment Periods. The wording ‘Retreatment’ was used because patients with plaque psoriasis in UNCOVER‐J (not included in this subanalysis) underwent retreatment during this period if certain criteria were met. Q2W, every 2 weeks; Q4W, every 4 weeks.